GAO, FDA identify tactics to fight economic adulteration

Manufacturer reluctance to share information about adulterated ingredients hinders the FDA from preventing this form of drug degradation, the agency told the U.S. Government Accountability Office. In addition, the regulator said segregating economic from other forms of adulteration--a distinction currently not made--would help it fight the practice. The GAO finds that the FDA needs better coordination of its many efforts to fight the scourge. GAO report (PDF)

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.